Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Health Affairs Scholar|June 11, 2026
Modification patents across multiple NDAs in pharmaceutical protectionsRobin Feldman, Ramy Alsaffar, Tanziuzzaman SakibHealth Affairs (Project Hope)|May 17, 2022
Understanding 'Evergreening': Making Minor Modifications Of Existing Medications To Extend ProtectionsRobin FeldmanJournal of Alzheimer'S Disease : JAD|April 12, 2021
Physicians Treating Alzheimer's Disease Patients Should Be Aware that Televised Direct-to-Consumer Advertising Links More Strongly to Drug Utilization in Older PatientsRobin FeldmanStanford Law Review|July 22, 2011
Whose body is it anyway? Human cells and the strange effects of property and intellectual property lawRobin FeldmanJournal of Law and the Biosciences|December 14, 2023
Leading with the trailing edge: facilitating patient choice for insulin productsRobin FeldmanPlos Medicine|April 25, 2024
Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars ActRobin FeldmanStanford Technology Law Review : STLR : an Online High-Technology Law Journal From Stanford Law School|September 16, 2014
Copyright at the Bedside: Should We Stop the Spread?Robin Feldman, John NewmanThe Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|March 4, 2024
NIH Licensing Would Benefit from Free-Market ProvisionsRobin Feldman, Zachary RosenPageof 2